Skjødt, M. K. http://orcid.org/0000-0002-2109-8989
Ernst, M. T.
Khalid, S. http://orcid.org/0000-0002-2845-5731
Libanati, C.
Cooper, C.
Delmestri, A. http://orcid.org/0000-0003-0388-3403
Rubin, K. H. http://orcid.org/0000-0001-5045-536X
Javaid, M. K.
Martinez-Laguna, D. http://orcid.org/0000-0001-5374-8176
Toth, E.
Prieto-Alhambra, D.
Abrahamsen, B. http://orcid.org/0000-0002-2730-6080
Funding for this research was provided by:
UCB
Article History
Received: 12 October 2020
Accepted: 11 February 2021
First Online: 15 March 2021
Declarations
:
: The study was approved by the Danish Medicines Agency, the Danish Data Protection Agency, and Statistics Denmark (ref. number 706638). For this type of studies, ethical committee approval is not required. For this type of study formal consent is not required.
: Not applicable.
: Given by all authors.
: MKS: Educational grant and institutional research grant, UCB.MTE: Institutional grant, UCB.SK: No conflict of interest.CL and ET: Employees of UCB pharma.CC: Personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB.AD: No conflict of interest.KHR: No conflict of interest.MKJ: Personal fees from Amgen and UCB, unrestricted grants from Amgen.DML: Consulting or speakers fees from Amgen, Lilly, Novartis, Italfarmaco, Ferrer and Rubió, outside the submitted work.DPA: Research grants from Amgen, Johnson & Johnson, and UCB. Consultation or speaker fees paid to my department by Amgen, Astellas, and UCB.BA: Institutional research grants UCB, Novartis. Consulting or speakers fees UCB, Kyowa-Kirin, Amgen, Eli-Lily, Pharmacosmos.